Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H1 2017


  • Products Id :- GMDHC9081IDB
  • |
  • Pages: 97
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura-Pipeline Review, H1 2017, provides an overview of the Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline landscape.

Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on lower legs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Thrombocytopenic Purpura-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 7, 5, 1 and 5 respectively.

Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

The pipeline guide reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Idiopathic Thrombocytopenic Purpura (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Hematological Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Hematological Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Overview

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Companies Involved in Therapeutics Development

3SBio Inc

Amgen Inc

arGEN-X BV

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CSL Ltd

Genosco Inc

Hansa Medical AB

Immunomedics Inc

Intas Pharmaceuticals Ltd

Jiangsu Hengrui Medicine Co Ltd

Merck & Co Inc

Momenta Pharmaceuticals Inc

Novartis AG

Pfizer Inc

PhytoHealth Corp

Protalex Inc

Rigel Pharmaceuticals Inc

UCB SA

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Drug Profiles

ARGX-113-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-655064-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltrombopag olamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fostamatinib disodium-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GL-2045-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2285921-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hetrombopag Olamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

letolizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-230-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-254-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-281-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8723-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHN-013-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRTX-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

romiplostim biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rozanolixizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKIO-703-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thrombopoietin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veltuzumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Dormant Projects

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Discontinued Products

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Product Development Milestones

Featured News & Press Releases

Dec 01, 2016: argenx to provide update on ARGX-113 during American Society of Hematology Annual Meeting

Sep 22, 2016: argenx provides update on lead program ARGX-113 at R&D day in New York

Sep 15, 2016: Rigel Restructures to Focus on Fostamatinib Commercialization

Aug 30, 2016: Rigel Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP

Aug 25, 2016: Health Canada issues advisory on REVOLADE citing risk of severe hepatotoxicity

Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder

May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association

Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP

Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP

Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag

Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP

Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP

Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder

Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by 3SBio Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Amgen Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by arGEN-X BV, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Boehringer Ingelheim GmbH, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Bristol-Myers Squibb Company, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by CSL Ltd, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Genosco Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Hansa Medical AB, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Immunomedics Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Merck & Co Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Momenta Pharmaceuticals Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Novartis AG, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Pfizer Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by PhytoHealth Corp, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Protalex Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Rigel Pharmaceuticals Inc, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by UCB SA, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Dormant Projects, H1 2017

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc, Amgen Inc, arGEN-X BV, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, CSL Ltd, Genosco Inc, Hansa Medical AB, Immunomedics Inc, Intas Pharmaceuticals Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, Momenta Pharmaceuticals Inc, Novartis AG, Pfizer Inc, PhytoHealth Corp, Protalex Inc, Rigel Pharmaceuticals Inc, UCB SA

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutic Products under Development, Key Players in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Pipeline Overview, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Pipeline, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Pipeline Assessment

select a license

Single User License
USD 2000 INR 129560
Site License
USD 4000 INR 259120
Corporate User License
USD 6000 INR 388680

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com